ImmunityBio, Inc. (NASDAQ:IBRX) Position Reduced by DekaBank Deutsche Girozentrale

DekaBank Deutsche Girozentrale reduced its position in shares of ImmunityBio, Inc. (NASDAQ:IBRX) by 4.3% in the second quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 196,200 shares of the company’s stock after selling 8,892 shares during the quarter. DekaBank Deutsche Girozentrale’s holdings in ImmunityBio were worth $1,234,000 as of its most recent SEC filing.

Several other hedge funds also recently modified their holdings of IBRX. Meridian Management Co. bought a new position in ImmunityBio during the fourth quarter valued at about $46,000. Private Advisor Group LLC bought a new position in shares of ImmunityBio during the 4th quarter valued at about $53,000. Simplicity Wealth LLC bought a new stake in shares of ImmunityBio in the 1st quarter worth approximately $58,000. Bleakley Financial Group LLC acquired a new stake in ImmunityBio during the first quarter valued at approximately $58,000. Finally, Lazard Asset Management LLC lifted its stake in ImmunityBio by 102.6% during the first quarter. Lazard Asset Management LLC now owns 13,019 shares of the company’s stock valued at $68,000 after purchasing an additional 6,593 shares during the last quarter. 8.58% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

Separately, Piper Sandler cut their price objective on ImmunityBio from $6.00 to $4.75 and set a “neutral” rating for the company in a research report on Monday, August 19th.

ImmunityBio Trading Up 1.8 %

Shares of IBRX opened at $3.48 on Friday. The business’s 50-day moving average price is $4.52 and its 200 day moving average price is $5.68. The stock has a market capitalization of $2.41 billion, a P/E ratio of -3.17 and a beta of 1.02. ImmunityBio, Inc. has a 1-year low of $1.25 and a 1-year high of $10.53.

ImmunityBio (NASDAQ:IBRX) last released its quarterly earnings results on Monday, August 12th. The company reported ($0.20) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.17) by ($0.03). The firm had revenue of $1.05 million for the quarter, compared to analyst estimates of $2.53 million. On average, research analysts predict that ImmunityBio, Inc. will post -0.86 earnings per share for the current year.

ImmunityBio Company Profile

ImmunityBio, Inc, a clinical-stage biotechnology company, engages in developing therapies and vaccines that bolster the natural immune system to defeat cancers and infectious diseases. Its platforms for the development of biologic product candidates include antibody-cytokine fusion proteins; DNA, RNA, and recombinant protein vaccines; and cell therapies.